Address
Forbion Capital Partners
2-35 Gooimeer
1411 DC Naarden
Netherlands
VCID: 21142
Profile
Corporate information
Official name
Forbion Capital Partners Management Services B.V.
Registration country
Affiliated entities
Affiliated entities
Forbion Capital Partners is a dedicated Life Sciences venture capital firm with offices in Naarden, The Netherlands, and Munich, Germany. Forbion invests in life sciences companies in drug discovery & development as well as medical device companies addressing substantial unmet medical needs. Forbion’s investment team of nine investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea, PanGenetics, Argenta Discovery and most recently Biovex and Pathway Medical. Current assets under management exceed $550m, split between four active funds and comprising some 29 promising portfolio companies. Forbion Capital Partners Fund II is supported by the European Investment Fund through its ERP and LfA facilities. Forbion co-manages Biogeneration Ventures, an early stage fund focused on (academic) spin-outs and seed investments in the Netherlands.
Funds managed
| Fund | Type | Vintage |
|---|---|---|
| Forbion Capital Fund III CV | Venture | 2015 |
Team
![[node:title] photo](/sites/default/files/styles/icon/public/default_images/icon-person.png?itok=8SSzz6Wf "[node:title] photo"){kind=icon}
Investments
Selected investments
| Company | Country | Date | Notes | ||
|---|---|---|---|---|---|
|
Allecra Therapeutics Developer of antibiotic treatments designed to combat multi drug-resistant gram-negative bacteria |
19 Apr 2013 | Series A Co-led the round., Active |
||
|
Bluebird Bio Inc Developer of an innovative gene therapies for severe genetic disorders |
United States | 1 Apr 2011 1 Jul 2012 1 Mar 2010 |
Series D |
|
|
Santaris Pharma A/S |
Denmark | 1 Jun 2012 | Venture Initial investment. Round participant. Active |
|
|
|
Mitralign Inc Percutaneous mitral valve repair system. |
United States | 1 May 2012 | Series D |
|
|
|
Argos Therapeutics Inc |
United States | 1 Apr 2008 1 Apr 2012 |
Series D |
|
|
|
CircuLite Inc Develops superficially implanted ventricular assist devices. |
Germany | 1 Jan 2010 1 Nov 2011 |
Series D |
|
|
|
PneumRx Inc Developer of minimally invasive treatments for emphysema patients. |
United States | 1 Jan 2011 | N/A |
|
|
|
Promedior Inc A biotechnology company developing novel biologic therapeutics to treat fibroproliferative diseases. |
United States | 1 Mar 2010 | Series C |
|
|
|
arGEN-X BV Innovation-driven biopharmaceutical company. |
Netherlands | 1 Sep 2009 | Series A |
|
|
|
Pathway Medical Technologies Inc Manufacturer of medical devices for the treatment of arterial disease. |
United States | 1 Apr 2008 1 Mar 2009 |
Series D |
|
|
|
Amakem NV |
Belgium | N/A |
||
|
|
AM-Pharma Holding BV |
Netherlands | N/A |
||
|
|
Biovex Inc Biotechnology company developing new generation biologics for the treatment of cancer and infectious disease. |
United States | Series E Active |
||
|
|
Transave Inc |
United States | N/A |